Unasnemab, identified by its CAS number 2379805-59-9, is a monoclonal antibody designed for therapeutic applications, particularly in the treatment of neurodegenerative diseases. It is engineered to target specific proteins involved in neuroinflammation and neurodegeneration, aiming to modulate immune responses in the central nervous system. The structure of Unasnemab consists of a variable region that binds to its target antigen, allowing for specificity in its action. Its mechanism of action typically involves inhibiting pathological processes associated with neurodegenerative conditions, potentially leading to neuroprotection and improved neuronal function. As a biologic, Unasnemab is produced using recombinant DNA technology, and its stability, solubility, and efficacy are influenced by factors such as formulation and storage conditions. Clinical studies are essential to evaluate its safety, pharmacokinetics, and therapeutic efficacy in humans. Overall, Unasnemab represents a promising approach in the field of neurotherapeutics, reflecting ongoing advancements in targeted biological treatments.

Unasnemab

2379805-59-9: Unasnemab, identified by its CAS number 2379805-59-9, is a monoclonal antibody designed for therapeutic applications, particularly in the treatment of neurodegenerative diseases. It is engineered to target specific proteins involved in neuroinflammation and neurodegeneration, aiming to modulate immune responses in the central nervous system. The structure of Unasnemab consists of a variable region that binds to its target antigen, allowing for specificity in its action. Its mechanism of action typically involves inhibiting pathological processes associated with neurodegenerative conditions, potentially leading to neuroprotection and improved neuronal function. As a biologic, Unasnemab is produced using recombinant DNA technology, and its stability, solubility, and efficacy are influenced by factors such as formulation and storage conditions. Clinical studies are essential to evaluate its safety, pharmacokinetics, and therapeutic efficacy in humans. Overall, Unasnemab represents a promising approach in the field of neurotherapeutics, reflecting ongoing advancements in targeted biological treatments.

<p>Unasnemab (MT-3921) binds RGMa, promoting neuroregeneration and locomotor function, showing potential for spinal cord injury and regenerative research.</p>

CAS 2379805-59-9

Unasnemab

Unasnemab

Ref: TM-T80900